Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin Monotherapy in T2DM
NCT00950599Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2003
- Primary completion
- May 2004
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of saxagliptin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started May 2003; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00950599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00950599.